This study is currently not recruiting participants.

A Phase 1 Open Label Multiple-Ascending-Dose Study of DS-2248 an Orally Bioavailable Heat Shock Protein 90 Inhibitor in Subjects with Advanced Solid Tumors

Investigation of the Safety and Tolerability of an Investigational Medication

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The purpose this study is to confirm the safety and tolerability of the study drug, DS-2248.

Detailed description of study

The purpose this study is to confirm the safety and tolerability of the study drug, DS-2248.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Advanced Solid Tumor
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the safety and tolerability of an investigational medication called DS-2248. Safety refers to how safe the medication is for people to use, while tolerability means how well people can handle the medication without severe side effects. This study aims to understand these aspects in participants who take the investigational medication.

Participants will receive the investigational medication and be monitored for any side effects or reactions. The study will involve regular check-ups and assessments to ensure participant safety and gather data on how the medication is tolerated.

  • Who can participate: Participants must be within the age range specified by the study, typically adults aged 18-65, and meet key eligibility factors, including specific health conditions or lack thereof, as per the study's requirements.
  • Study details: Participants will take the investigational medication and attend regular check-ups to monitor safety and tolerability. An inactive substance that looks like the investigational medicine but does not contain any medicine may also be used for comparison.
Updated on 19 Feb 2024. Study ID: 1207009083

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team